The challenge of managing coexistent type 2 diabetes and obesity
Potential new treatments include analogues of intestinal and adipocyte hormones, inhibitors of renal glucose reabsorption and cellular glucocorticoid activation, and activators of cellular energy production (BMJ)
Strategic high impact changes: childhood obesity
Over 23% of our 4–5-year-olds are now overweight or obese, as well as over 33% of our 10–11-year-olds. One in five mothers are currently estimated to be overweight or obese (Department of Health, UK)
IDF Charter promotes rights of people with diabetes
The International Diabetes Federation (IDF) has launched the first ever Charter setting out the fundamental rights of more than 300 million people living with diabetes (IDF)
Testosterone replacement may improve death rate in testosterone-deficient men with diabetes
A new study of men with type 2 diabetes showed that those with low testosterone levels may die sooner unless they are given testosterone replacement therapy (Endocrine Today)
Deficient brain insulin signaling pathway in Alzheimer’s disease and diabetes
Our findings provide novel insight into the molecular mechanism by which type 2 diabetes mellitus increases the risk for developing cognitive impairment and dementia in Alzheimer’s disease (Journal of Pathology)
Diabetes mellitus and risk of pancreatic cancer: A meta-analysis of cohort studies
Findings from this meta-analysis strongly support that diabetes is associated with an increased risk of PaC in both males and females and that DM is both an early manifestation and an etiologic factor of pancreatic cancer (European Journal of Cancer)
Hypoglycemia: An impact beyond numbers
The information on this site is intended for health care professionals in the United States and is not intended for the general public (Discusshypo)
Biphasic Insulin Analogs for Treatment of Diabetes: A Review
Data suggest that biphasic insulin analogs are superior to long- or intermediate-acting insulin in obtaining good metabolic control (Internet Journal of Family Practice)
Autoantigen Based Vaccines for Type 1 Diabetes
This vaccine strategy has shown increasing promise for effective, safe, and persistent suppression of ß-cell specific autoimmunity (Discovery Medicine)
More positive data for Sanofi/Zealand diabetes drug
Sanofi-Aventis and Zealand Pharma have unveiled yet more impressive late-stage data showing that their investigational diabetes drug lixisenatide reduced HbA1c and delivered a significant decrease in weight loss (PharmaTimes)
Glycosmedia is also available as an App: